NATERA INC (NTRA)

Here Are Billionaire Stanley Druckenmiller's 5 Biggest Stock Holdings

Court Grants Natera’s Request to Include Additional Patent in its Lawsuit Against NeoGenomics

Exploring NASDAQ:NTRA's high growth characteristics.

Why the high growth investor may take a look at NATERA INC (NASDAQ:NTRA).

Natera Announces Enrollment of First Patients in SAGITTARIUS: a Randomized, Phase III Clinical Trial in Colon Cancer

Natera and MyOme Announce Launch of iPRS™ for Breast Cancer Risk Assessment

Natera Larger Than S&P 500 Component Teledyne Technologies

Clinical Validation Study on Natera’s Fetal RhD NIPT Published in Obstetrics & Gynecology

Natera Announces Medicare Coverage for Prospera™ in Single Lung Transplant Recipients

Natera to Present New SignateraTM Data in Multiple Abstracts at the San Antonio Breast Cancer Symposium

Federal Court Jury Issues Unanimous Verdict that Natera Engaged in False Advertising and Unfair Competition in Deliberate Attempt to Damage Guardant Health's Colorectal Cancer Test, Guardant Reveal™

/PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH) ("Guardant Health"), a leading precision oncology company, today announced that a jury in the U.S. District...

Natera Issues Statement on Guardant Health Litigation

Natera Co-Founder and Executive Chairman Matthew Rabinowitz Named 2024 R&D Leader of the Year

Natera Announces Publication of over 100 Peer-Reviewed Papers on SignateraTM

Here Are Billionaire Stanley Druckenmiller's 5 Biggest Stock Holdings

NTRA May 2025 Options Begin Trading

Natera Reports Third Quarter 2024 Financial Results

Natera Announces Completion of Signatera™ Analysis from the CALGB (Alliance)/SWOG 80702 Randomized, Phase III Clinical Trial in Colorectal Cancer

Notable Monday Option Activity: NVAX, NTRA, ALB

Natera to Participate in Upcoming Investor Conferences

Natera to Report its Third Quarter 2024 Results on November 12, 2024

Natera to Present New Renasight Data at ASN Kidney Week 2024